How biotechs can strengthen their value story with advanced analytics
Small and emerging companies must make big decisions about what to do with their assets early in development. Should they seek venture capital (VC) funding to develop a product themselves or seek a partner once it shows clinical activity? They need to know their product candidate’s value and commercial viability to make the right decision, including the market size, growth and revenue potential.
Recent advances in machine learning and predictive analytics have empowered health economics and outcomes research (HEOR). Sophisticated tools are now available to help build a data-driven value story that can help attract investors and partners, convince payers, and benefit patients. Here are five ways biotech companies can enhance their value story with advanced analytics.
Related Insights
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Related Insights
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Article
Cyber security 101: Tips to protect your site from a cyber threat
Oct 13, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026